NSRX Nasus Pharma Ltd
Fundamentals / CIK 0002029039 / USDNasus Pharma Ltd reported $1.24B in revenue and a net loss of $5.86M for the fiscal year ended December 31, 2025, with a -0.4% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open NSRX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$1.24B Dec 31, 2025
-
Operating Income FY 2025-$4.90M -0.4% margin
-
Net Income FY 2025-$5.86M -0.5% net margin
-
Diluted EPS FY 2025-$0.72 Split-adjusted
-
Free Cash Flow FY 2025-$4.93M -0.4% FCF margin
-
Cash & ST Investments Dec 31, 2025$1.24M Total debt: $118K
Annual revenue and net income
3 fiscal years (2023 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Revenue | $1.24B | -- | -- |
| Research & Development | $2.24M | $335K | $567K |
| Total Operating Expenses | $4.90M | $1.08M | $1.15M |
| Operating Income | -$4.90M | -$1.08M | -$1.15M |
| Interest Expense | -$78K | $29K | $49K |
| Net Income | -$5.86M | -$1.53M | -$1.05M |
| Basic EPS | -$0.72 | -$0.22 | -$0.15 |
| Diluted EPS | -$0.72 | -$0.22 | -$0.20 |
| Basic Shares Outstanding | 8.0M | 7.0M | 6.9M |
| Diluted Shares Outstanding | 8.0M | 7.0M | 7.1M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 |
|---|---|---|
| Cash & Cash Equivalents | $1.24M | $284K |
| Cash & Short-Term Investments | $1.24M | $284K |
| Other Current Assets | $186K | $29K |
| Total Current Assets | $4.86M | $457K |
| Property, Plant & Equipment, Net | $14K | -- |
| Total Non-Current Assets | $149K | $260K |
| Total Assets | $5.00M | $717K |
| Accounts Payable | $829K | $651K |
| Total Current Liabilities | $2.16M | $3.93M |
| Total Non-Current Liabilities | $73K | $0 |
| Total Liabilities | $2.24M | $3.93M |
| Total Debt (incl. Leases) | $118K | -- |
| Common Stock | -- | $20K |
| Retained Earnings | -$18.52M | -$12.66M |
| Total Stockholders' Equity | $2.77M | -$3.21M |
| Total Equity | $2.77M | -$3.21M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $1.24M | $284K |
| Cash & Short-Term Investments | $1.24M | $284K |
| Other Current Assets | $186K | $29K |
| Total Current Assets | $4.86M | $457K |
| Property, Plant & Equipment, Net | $14K | -- |
| Total Non-Current Assets | $149K | $260K |
| Total Assets | $5.00M | $717K |
| Accounts Payable | $829K | $651K |
| Total Current Liabilities | $2.16M | $3.93M |
| Total Non-Current Liabilities | $73K | $0 |
| Total Liabilities | $2.24M | $3.93M |
| Total Debt (incl. Leases) | $118K | -- |
| Common Stock | -- | $20K |
| Retained Earnings | -$18.52M | -$12.66M |
| Total Stockholders' Equity | $2.77M | -$3.21M |
| Total Equity | $2.77M | -$3.21M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Net Income | -$5.86M | -$1.53M | -$1.05M |
| Stock-Based Compensation | $447K | $10K | $39K |
| Change in Payables | $152K | -$5.0K | -$116K |
| Operating Cash Flow | -$4.92M | -$665K | -$1.03M |
| Capital Expenditure | -$14K | -- | -- |
| Free Cash Flow | -$4.93M | -- | -- |
| Investing Cash Flow | -$3.01M | -- | -- |
| Common Stock Issued | $8.48M | -- | -- |
| Financing Cash Flow | $8.92M | $770K | $1.05M |
| Net Change in Cash | $980K | $101K | $39K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Operating Margin | -0.4% | -- | -- |
| Net Profit Margin | -0.5% | -- | -- |
| Return on Equity (ROE) | -211.6% | -- | -- |
| Return on Assets (ROA) | -117.0% | -213.7% | -- |
| Current Ratio | 2.24x | 0.12x | -- |
| Quick Ratio | 0.57x | 0.07x | -- |
| Debt to Equity | 0.04x | -- | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.